November 13, 2025 – The "2025 Forbes China 50 Most Innovative Companies" list was officially announced. Biokin Pharmaceutical was once again selected for this prestigious list, recognized for its exceptional innovative capabilities, solidifying its position as one of the few pharmaceutical companies to be included for two consecutive years.

The evaluation framework for this year's list encompasses multiple dimensions. These include Innovation Capacity (corporate R&D investment and core intellectual property), Corporate Governance (level of digitalization and management expertise), Growth Potential (performance of key financial indicators over the past three years), Market Advantage Driven by Innovation (market share of core products and product substitutability), as well as Corporate Social Image.

Leveraging its synergistic dual R&D center structure spanning both China and the United States, Biokin Pharmaceutical has efficiently advanced multiple innovative drug candidates into clinical stages. In a significant milestone, September 2025 saw the Investigational New Drug (IND) application for Biokin's first Antibody-Radionuclide Conjugate (ARC) drug, Lutetium [177Lu]-BL-ARC001 Injection, receive implicit approval. This drug is a potential global first-in-class ARC with wholly independent intellectual property rights owned by Biokin. It not only addresses a gap in the domestic nuclear drug R&D landscape but also demonstrates stronger target specificity, higher tumor enrichment, and the potential for superior resistance mitigation compared to traditional radionuclide conjugates, further validating Biokin Pharmaceutical's leading prowess in innovative R&D.

China's economic growth is inextricably linked to technological innovation, which also serves as the core driver for Biokin Pharmaceutical. Moving forward, we will continue to increase investment in research and development, striving to bring more innovative drugs to the global market and benefit a broader patient population.